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Abstract
Background: Prescribing psychotropic drugs in clients with severe anaemia has rarely been
reported before.
Case Presentation: A 36 year old man with severe anaemia was prescribed divalproex sodium
250 mg daily for mood swings. He had unbearable side effects and had to discontinue the
medication in nine days.
Conclusion: Divalproex sodium may result in severe side effects in clients with severe anaemia.
Background
Prescribing psychotropic medications is a challenge in
those whose physiological functions are disturbed. Treat-
ing a mental health problem in a patient suffering from
severe anaemia, could be even more challenging. There is
very little evidence on prescribing in such a clinical sce-
nario and even anecdotal reports and case reports can be
used as a guide.
This case report discusses the use of divalproex sodium in
a client with severe anaemia.
Case presentation
Mr AB a 36 year old gentleman, bilateral amputee above
knee, with a possible diagnosis of personality disorder
had been self harming by cutting himself on the arms for
many years. This consistent self harm caused chronic iron
deficiency anaemia, which failed to respond to iron sup-
plements. He had consistently refused to take psycho-
tropic medicines because they had either not worked or
had given him unbearable side effects. Concerned at his
deteriorating haemoglobin levels, we conducted an
assessment to ascertain what the client's mental health
needs were.
Over 2006, his Hb level had fallen from around 5 g/dl to
4 g/dl (N = 13.5–18.0 g/dl) and he continued to self harm.
All other physiological functions (liver, renal) were within
normal limits. After some discussion he agreed to start
divalproex sodium at 250 mg daily with the aim of grad-
ually increasing the dose, so that his mood swings might
be tackled and perhaps help him to reduce self harm. He
was not depressed and he did not want any antidepres-
sants. He felt negative towards social services, and mental
health services.
After a few days, he began having "hot sweats, scratching
(himself), self harm worsening, heart pain in the middle
of the chest, twitch movements in arms, loss of appetite,
less sleep, worse moods and palpitations". He persisted
with the medication for a total of 9 days by when he had
also been "scratching (his) head till it was bleeding, hav-
ing blood in stools, and feeling that (his) skin was turning
yellow". In consultation with the mental health team he
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stopped divalproex sodium. Within three days he
reported that his sleep was better, that he did not feel the
urge to scratch himself as much as before and that his self
harm had returned to the level it was before starting dival-
proex sodium. He still felt irritable but this remitted in
one week, after which he felt things had returned to "nor-
mal".
Discussion
Clients with poor physiological functions pose challenges
to clinicians who want to prescribe medications which
have not been used in such situations. Severe iron defi-
ciency anaemia is a scenario that is unusual in clinical
practice.
This client had a gradual deterioration in his haemo-
globin (Hb) level thought to be caused by consistent self
harm for many years. He had not responded to antide-
pressants in the past and had a list of medications to
which he had suffered "allergic" reaction to in the past.
These included erythromycin, trimipramine, co-amoxi-
clav, and flupenthixol.
Divalproex sodium was advised to treat his mood swings
which had been identified in the past to be of concern.
Valproic acid has been used in Diamond-Blackfan anae-
mia as a therapeutic agent [1,2] although it is known to
cause haematological toxicity [3]. No other case reports
were found on a Medline/PUBMED search (valproate
anaemia; limits: case reports) on the therapeutic use of
valproate in a patient suffering from anaemia.
The intensity and the number of side effects that the low
dose of divalproex caused in this client, may suggest his
sensitivity to the compound. There is mention of patients
with valproate associated idiosyncratic drug reactions
(IDR) having deficient erythrocyte glutathione peroxidase
activity, low plasma selenium concentrations, low COP1
ratios, and low COP2 ratios compared with age-matched
controls [4]. We did not measure any of those parameters
but it is something that any further anecdotal use could
test.
Alternatively, these adverse effects could be a direct or
indirect result of his physiological status-severe anaemia.
Other clinicians who may be looking at using divalproex
sodium in a patient having anaemia should be cautious.
Conclusion
Divalproex sodium may result in severe side effects in cli-
ents with severe anaemia.
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